Table 2.
Risk of NHL subtypes associated with measures of genome-wide homozygosity, FROH and F3*
| FROH | F3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Subtype | β | SE | P-value | I 2 | P het | β | SE | P-value | I 2 | P het |
| CLL | 21.14 | 4.41 | 1.59 × 10−6 | 0.0% | 0.42 | 27.46 | 6.51 | 2.44 × 10−5 | 49.7% | 0.11 |
| DLBCL | 0.04 | 10.89 | 1.0 | 72.5% | 0.01 | 1.96 | 9.57 | 0.84 | 82.4% | 0.001 |
| FL | 11.39 | 5.82 | 0.02 | 5.3% | 0.37 | 13.19 | 8.01 | 0.10 | 64.2% | 0.04 |
| MZL | −0.87 | 7.88 | 0.91 | 6.40 | 5.20 | 0.22 | ||||
*
Estimates of the log odds (β), standard error (SE), and P-value are provided for the association between FROH and F3 and each subtype, adjusted for age, sex (except UCSF1/NHS), percentage of missing SNPs, and principal components and combined using random effects meta-analysis. The I2 statistic provides an estimate of heterogeneity in association estimates across GWAS, and Phet is the P-value for heterogeneity among studies. FROH: Fraction of runs of homozygosity; NHL: non-Hodgkin lymphoma; CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MZL: marginal zone lymphoma.